Medigen Biotechnology Corp. (TPEX:3176)
Taiwan · Delayed Price · Currency is TWD 34.40
-0.55 (-1.57%)
Aug 19, 2026, 10:24 AM CST
Medigen Biotechnology Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,269 | 1,583 | 1,373 | 1,158 | 1,056 | 3,922 |
Revenue Growth | -22.05% | 15.28% | 18.57% | 9.64% | -73.08% | 537.16% |
Gross Profit Gross Profit Growth | 657.17 | 905.02 | 753.76 | 617.33 | 87.46 | 2,551 |
Operating Income Operating Income Growth | -243.68 | -156.99 | -217.2 | -1,233 | -1,667 | 779.96 |
Net Income Net Income Growth | -252.36 | -108.8 | -204.69 | -561.3 | -675.87 | -52.61 |
Earnings Per Share EPS Growth | -1.82 | -0.78 | -1.47 | -4.03 | -4.86 | -0.38 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Nucleic Acid Inspection Department Nucleic Acid Inspection Department Growth | 262.05 | 269.26 | 64.84 | 61.73 | 83.79 | 98.34 |
New Drug and Vaccine Development Department New Drug and Vaccine Development Department Growth | 603.68 | 613.17 | 605.64 | 389.62 | 365.04 | 3,275 |
Adjustment and Elimination Adjustment and Elimination Growth | -0.32 | -0.32 | -2.31 | -2.7 | - | - |
Generic Drugs, Medical Beauty Products and Health Food Departments Generic Drugs, Medical Beauty Products and Health Food Departments Growth | 675.51 | 700.07 | 695.08 | 709.07 | 606.52 | 536.53 |
Cell Therapy Department Cell Therapy Department Growth | - | 0.32 | 9.45 | - | 0.6 | 11.98 |
Total Total Growth | 1,345 | 1,583 | 1,373 | 1,158 | 1,056 | 3,922 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,724 | 2,485 | 2,574 | 4,588 | 5,135 | 2,998 |
Total Debt Total Debt Growth | 982.69 | 911.25 | 1,018 | 2,865 | 2,774 | 992.07 |
Net Cash (Debt) Net Cash Growth | 1,742 | 1,574 | 1,555 | 1,723 | 2,361 | 2,006 |
Net Cash Growth | 14.65% | 1.21% | -9.72% | -27.03% | 17.68% | 85.87% |
Net Cash Per Share Net Cash Per Share Growth | 12.56 | 11.30 | 11.16 | 12.36 | 16.97 | 14.44 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -63.1 | 40.55 | 37.92 | -503.52 | -1,138 | 518.12 |
Capital Expenditures CapEx Growth | -419.95 | -71.47 | -56.51 | -38.41 | -148.16 | -142.96 |
Free Cash Flow Free Cash Flow Growth | -483.05 | -30.92 | -18.59 | -541.93 | -1,286 | 375.16 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 51.80% | 57.19% | 54.91% | 53.32% | 8.28% | 65.05% |
Operating Margin | -19.21% | -9.92% | -15.82% | -106.51% | -157.87% | 19.89% |
Pretax Margin | -22.63% | -13.81% | -8.21% | -110.46% | -177.34% | 28.98% |
Profit Margin | -19.89% | -6.88% | -14.91% | -48.48% | -64.01% | -1.34% |
FCF Margin | -38.08% | -1.95% | -1.35% | -46.81% | -121.82% | 9.57% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 41.51 | 41.51 | 41.51 | 41.51 | 41.51 |
P/FCF Ratio | - | - | - | - | - | 21.32 |
PS Ratio | 3.84 | 2.85 | 3.29 | 5.39 | 4.44 | 2.04 |